NASDAQ:EVFM - Evofem Biosciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.56 -0.04 (-1.11 %)
(As of 02/20/2019 06:00 AM ET)
Previous Close$3.60
Today's Range$3.52 - $3.60
52-Week Range$1.79 - $8.50
Volume6,411 shs
Average Volume21,653 shs
Market Capitalization$92.10 million
P/E RatioN/A
Dividend YieldN/A
Beta1.56
Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women. The company is also developing vaginal gel product candidate for the treatment of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Receive EVFM News and Ratings via Email

Sign-up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVFM
CUSIPN/A
Phone858-550-1900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.17 per share

Profitability

Net Income$-9,990,000.00

Miscellaneous

Employees23
Market Cap$92.10 million
OptionableNot Optionable

Evofem Biosciences (NASDAQ:EVFM) Frequently Asked Questions

What is Evofem Biosciences' stock symbol?

Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."

How were Evofem Biosciences' earnings last quarter?

Evofem Biosciences Inc (NASDAQ:EVFM) announced its quarterly earnings data on Friday, August, 10th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.63. View Evofem Biosciences' Earnings History.

When is Evofem Biosciences' next earnings date?

Evofem Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for Evofem Biosciences.

What price target have analysts set for EVFM?

5 analysts have issued 12-month price targets for Evofem Biosciences' shares. Their forecasts range from $8.00 to $15.00. On average, they expect Evofem Biosciences' share price to reach $10.70 in the next year. This suggests a possible upside of 200.6% from the stock's current price. View Analyst Price Targets for Evofem Biosciences.

What is the consensus analysts' recommendation for Evofem Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evofem Biosciences.

What are Wall Street analysts saying about Evofem Biosciences stock?

Here are some recent quotes from research analysts about Evofem Biosciences stock:
  • 1. According to Zacks Investment Research, "Evofem Biosciences Inc. develops and anticipates commercializing products which support and promote women as the primary healthcare consumer. The company is identifying and developing new and novel products which specifically address unmet needs in the areas of sexual and reproductive health, the prevention of acquisition of sexually transmitted infections and products which address or promote general health and wellbeing. Evofem Biosciences Inc., formerly known as Neothetics Inc., is based in SAN DIEGO CA. " (2/6/2019)
  • 2. Cantor Fitzgerald analysts commented, "We believe Evofem Biosciences is well-positioned to introduce an important new product, Amphora, the company’s proprietary multi-purpose vaginal pH regulator (MVP-R). As a non-hormonal contraceptive, we believe Amphora will appeal to women who desire to avoid use of hormone-based products out of concern for safety and side effects. Successful development of Amphora (or other MVP-Rs) to treat conditions of the vagina, e.g., infection with chlamydia or other bacteria, could create attractive opportunities that meaningfully expand the commercial potential, we believe." (12/17/2018)
  • 3. HC Wainwright analysts commented, "We utilize a discounted cash flow (DCF)-based approach, with a 15% discount rate and an effective tax rate of 30% applied to all future cash flows. Our probability of success for Amphora in contraception is 70%, which translates into a risk-adjusted net present value (rNPV) of $250M." (8/29/2018)

Has Evofem Biosciences been receiving favorable news coverage?

Media coverage about EVFM stock has been trending neutral recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Evofem Biosciences earned a coverage optimism score of 0.3 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the near term.

Who are some of Evofem Biosciences' key competitors?

Who are Evofem Biosciences' key executives?

Evofem Biosciences' management team includes the folowing people:
  • Ms. Saundra Pelletier, CEO & Director
  • Mr. Justin J. File, Chief Financial Officer
  • Dr. Kelly Culwell, Chief Medical Officer
  • Mr. Alexander A. Fitzpatrick, Exec. VP, Gen. Counsel & Sec. (Age 52)
  • Mr. Tim Glennon, VP of Sales & Marketing

Who are Evofem Biosciences' major shareholders?

Evofem Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.42%) and Geode Capital Management LLC (0.28%). Company insiders that own Evofem Biosciences stock include Alexander A Fitzpatrick, Kelly Culwell, Ltd Invesco, Russell Barrans, Saundra L Pelletier and Thomas G Lynch. View Institutional Ownership Trends for Evofem Biosciences.

Which major investors are selling Evofem Biosciences stock?

EVFM stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Evofem Biosciences.

Which major investors are buying Evofem Biosciences stock?

EVFM stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC. Company insiders that have bought Evofem Biosciences stock in the last two years include Alexander A Fitzpatrick, Kelly Culwell, Ltd Invesco, Russell Barrans, Saundra L Pelletier and Thomas G Lynch. View Insider Buying and Selling for Evofem Biosciences.

How do I buy shares of Evofem Biosciences?

Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Evofem Biosciences' stock price today?

One share of EVFM stock can currently be purchased for approximately $3.56.

How big of a company is Evofem Biosciences?

Evofem Biosciences has a market capitalization of $92.10 million. Evofem Biosciences employs 23 workers across the globe.

What is Evofem Biosciences' official website?

The official website for Evofem Biosciences is http://www.evofem.com.

How can I contact Evofem Biosciences?

Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-550-1900 or via email at [email protected]


MarketBeat Community Rating for Evofem Biosciences (NASDAQ EVFM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  148 (Vote Outperform)
Underperform Votes:  114 (Vote Underperform)
Total Votes:  262
MarketBeat's community ratings are surveys of what our community members think about Evofem Biosciences and other stocks. Vote "Outperform" if you believe EVFM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVFM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel